AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
81_CD
5Taxation_NOMZ
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
,_,
was_VBD
as_IN
follows_VPRT
:_:
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
UK_NN
1,123_CD
879_CD
741_CD
Overseas_PLACE
3,962_CD
3,323_CD
3,296_CD
5,085_CD
4,202_CD
4,037_CD
Taxes_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
UK_NN
taxation_NOMZ
Corporation_NOMZ
tax_NN
379 142 165_CD
Double_RB
taxation_NOMZ
relief_NN
22_CD
23_CD
29_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
178_CD
Deferred_JJ
taxation_NOMZ
45_CD
102 24 224 221_CD
160_CD
Overseas_PLACE
taxation_NOMZ
Overseas_PLACE
taxes_NN
992 783 929_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
7_CD
26_CD
51_CD
Deferred_JJ
taxation_NOMZ
31 113 139_CD
1,030_CD
922_CD
1,017_CD
Tax_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
1,254_CD
1,143_CD
1,177_CD
UK_NN
and_CC
overseas_PLACE
taxation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
at_PIN
current_JJ
rates_NN
on_PIN
the_DT
profits_NN
earned_VBN [WZPAST]
for_PIN
the_DT
periods_NN
covered_VBN [WZPAST]
by_PIN
the_DT
Group_NN
Financial_NN
Statements_NOMZ
._.
The_DT
prior_JJ
period_NN
adjustment_NOMZ
in_PIN
respect_NN
of_PIN
UK_NN
taxation_NOMZ
relates_VPRT
to_PIN
the_DT
settlement_NOMZ
of_PIN
a_DT
number_NN
of_PIN
tax_NN
issues_NN
covering_VBG [WZPRES]
several_QUAN
accounting_GER
periods_NN
including_VBG [WZPRES]
merger_NN
costs_NN
,_,
divestment_JJ
provisions_NN
and_CC
fixed_VBN
asset_NN
valuations_NOMZ
._.
Deferred_JJ
tax_NN
profit_NN
and_PHC
loss_NN
account_VPRT
amounts_NN
arise_VB
principally_RB
in_PIN
respect_NN
of_PIN
the_DT
origination_NOMZ
and_PHC
reversal_NN
of_PIN
timing_NN
differences_NN
._.
To_PIN
the_DT
extent_NN
that_TOBJ
dividends_NN
remitted_VBN [WZPAST]
from_PIN
overseas_PLACE
subsidiaries_NN
,_,
joint_JJ
ventures_NN
and_PHC
associates_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
result_VB
in_PIN
additional_JJ
taxes_NN
,_,
appropriate_JJ
amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
for_PIN [STPR]
._.
No_SYNE
deferred_JJ
tax_NN
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
for_PIN
unremitted_JJ
earnings_GER
of_PIN
Group_NN
companies_NN
overseas_PLACE
as_IN
these_DEMP
are_VPRT
,_,
in_PIN
the_DT
main_JJ
,_,
considered_VBN [PRIV] [PASTP]
permanently_RB
employed_VBN
in_PIN
the_DT
businesses_NOMZ
of_PIN
these_DEMO
companies_NN
and_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
,_,
the_DT
taxes_NN
would_PRMD
not_XX0
be_VB
material_NN
._.
Cumulative_JJ
unremitted_JJ
earnings_GER
of_PIN
overseas_PLACE
subsidiaries_NN
and_CC
related_VBN
undertakings_GER
totalled_VBD
approximately_RB
$_$
11,073_CD
m_NN [BEMA]
at_PIN
31_CD
December_NN
2004_CD
2003_CD
$_$
9,381_CD
m._FW
Unremitted_JJ
earnings_GER
may_POMD
be_VB [BEMA]
liable_PRED
to_PIN
overseas_PLACE
taxes_NN
and_CC
or_CC
UK_NN
taxation_NOMZ
after_IN
allowing_VBG [SUAV]
for_PIN
double_JJ
taxation_NOMZ
relief_NN
if_COND
they_TPP3
were_VBD
to_TO
be_VB [PASS]
distributed_VBN
as_IN
dividends_NN
._.
Exceptional_JJ
items_NN
included_VBN [WZPAST]
in_PIN
tax_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
:_:
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Tax_NN
credit_NN
on_PIN
exceptional_JJ
items_NN
67_CD
Includes_VPRT
deferred_JJ
tax_NN
relief_NN
of_PIN
$_$
9m_CD
2003_CD
$_$
nil_CD
,_,
2002_CD
$_$
nil_JJ
._.
The_DT
tax_NN
credit_NN
on_PIN
exceptional_JJ
items_NN
includes_VPRT
an_DT
amount_NN
of_PIN
$_$
58m_CD
arising_VBG
from_PIN
an_DT
agreement_NOMZ
with_PIN
the_DT
US_FPP1
tax_NN
authority_NOMZ
to_TO
allow_VB [SUAV]
$_$
170m_CD
of_PIN
the_DT
Zoladex_NN
settlement_NOMZ
originally_TIME
accrued_VBN
in_PIN
2002_CD
and_CC
paid_VBN
in_PIN
2003_CD
as_IN
deductible_JJ
for_PIN
tax_NN
._.
There_EX
is_VPRT
also_RB
a_DT
tax_NN
credit_NN
of_PIN
$_$
9m_CD
arising_VBG
on_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
disposal_NN
of_PIN
Advanta_NN
BV_NN
._.
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
In_PIN
certain_JJ
circumstances_NN
,_,
tax_NN
charges_NN
or_CC
credits_NN
on_PIN
currency_NN
translation_NOMZ
differences_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
via_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
tax_NN
charge_NN
on_PIN
such_JJ
currency_NN
translation_NOMZ
differences_NN
amounted_VBD
to_TO
$_$
nil_CD
in_PIN
2004_CD
2003_CD
$_$
nil_CD
,_,
2002_CD
$_$
2m_CD
and_CC
has_VPRT [PEAS]
been_VBN [PASS]
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
tax_NN
credit_NN
on_PIN
other_JJ
consolidation_NOMZ
exchange_NN
adjustments_NOMZ
taken_VBN [WZPAST]
to_PIN
reserves_NN
amounted_VBD
to_TO
$_$
22m_CD
in_PIN
2004_CD
2003_CD
$_$
66m_CD
,_,
2002_CD
$_$
135m_CD
._.
The_DT
movement_NOMZ
in_PIN
reserves_NN
via_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
also_RB
includes_VPRT
a_DT
tax_NN
credit_NN
of_PIN
$_$
357m_CD
,_,
arising_VBG [PRESP]
from_PIN
agreement_NOMZ
with_PIN
the_DT
tax_NN
authorities_NOMZ
to_TO
allow_VB [SUAV]
a_DT
proportion_NOMZ
of_PIN
certain_JJ
foreign_JJ
exchange_NN
losses_NN
arising_VBG [WZPRES]
on_PIN
intra-group_JJ
balances_NN
in_PIN
2000_CD
._.
Factors_NN
affecting_VBG [WZPRES]
future_JJ
tax_NN
charges_NN
As_IN
a_DT
group_NN
involved_VBN [WZPAST]
in_PIN
worldwide_JJ
operations_NOMZ
,_,
AstraZeneca_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
several_QUAN
factors_NN
that_TSUB
may_POMD
affect_VB
future_JJ
tax_NN
charges_NN
,_,
principally_RB
the_DT
levels_NN
and_PHC
mix_NN
of_PIN
profitability_NOMZ
in_PIN
different_JJ
jurisdictions_NOMZ
,_,
transfer_NN
pricing_GER
policies_NN
and_PHC
tax_NN
levels_NN
imposed_VBN
._.
A_DT
number_NN
of_PIN
material_NN
items_NN
currently_RB
under_IN
audit_NN
and_PHC
negotiation_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
detail_NN
in_PIN
Note_NN
30_CD
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
82_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
5Taxation_JJ
continued_VBN
Tax_NN
reconciliation_NOMZ
to_PIN
UK_NN
statutory_JJ
rate_NN
The_DT
table_NN
shown_VBN [PRIV]
below_PLACE
reconciles_NN
the_DT
UK_NN
statutory_JJ
tax_NN
charge_NN
to_PIN
the_DT
Groups_NN
current_JJ
tax_NN
charge_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
._.
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
5,085_CD
4,202_CD
4,037_CD
Notional_NN
taxation_NOMZ
charge_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
30_CD
%_NN
for_PIN
2003_CD
,_,
30_CD
%_NN
for_PIN
2002_CD
1,525_CD
1,261_CD
1,211_CD
Differences_NN
in_PIN
effective_JJ
overseas_PLACE
tax_NN
rates_NN
55 159 141_CD
Capital_NN
allowances_NN
tax_NN
reliefs_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
33 291 291_CD
Untaxed_JJ
reserves_NN
186_CD
51_CD
75_CD
Other_JJ
timing_NN
differences_NN
145_CD
168_CD
35_CD
Items_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
38_CD
80_CD
49_CD
Items_NN
not_XX0
chargeable_JJ
for_PIN
tax_NN
purposes_NN
71_CD
88_CD
110_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
171_CD
26_CD
51_CD
Exceptional_JJ
items_NN
124_CD
105_CD
Current_JJ
tax_NN
charge_NN
for_PIN
the_DT
year_NN
1,178_CD
928_CD
1,014_CD
Balance_NN
sheet_NN
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Deferred_VBN
taxation_NOMZ
liability_NOMZ
asset_NN
movement_NOMZ
At_PIN
beginning_GER
of_PIN
year_NN
693 359 212_CD
Profit_NN
and_PHC
loss_NN
account_NN
76 215 163_CD
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
78_CD
155_CD
Disposal_NN
of_PIN
subsidiary_NN
undertakings_GER
4_CD
13_CD
Exchange_NN
112 132 139_CD
At_PIN
end_NN
of_PIN
year_NN
799 693 359_CD
Debtors_NN
amount_NN
due_JJ
within_PIN
one_CD
year_NN
Note_NN
13 623 732 625_CD
Debtors_NN
amount_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Note_NN
13 159 165 226_CD
Provisions_NN
Note_VPRT [PRIV]
19_CD
1,581_CD
1,590_CD
1,210_CD
799 693 359_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
83_CD
5Taxation_NOMZ
continued_VBD
Deferred_JJ
taxation_NOMZ
The_DT
amounts_NN
of_PIN
deferred_VBN
taxation_NOMZ
accounted_VBD
for_PIN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
,_,
before_IN
netting_VBG
off_PIN
of_PIN
balances_NN
within_PIN
countries_NN
,_,
comprised_VBD
the_DT
following_JJ
deferred_JJ
tax_NN
liabilities_NOMZ
and_PHC
assets_NN
:_:
2004_CD
2003_CD
$_$
m_CD
$_$
m_CD [PASS]
Deferred_VBN
tax_NN
liabilities_NOMZ
UK_NN
fixed_VBN
assets_NN
609_CD
501_CD
Non-UK_JJ
fixed_JJ
assets_NN
767_CD
735_CD
Interest_NN
accruals_VPRT
28_CD
18_CD
Untaxed_JJ
reserves_NN
360_CD
137_CD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
194_CD
86_CD
Other_JJ
89_CD
175_CD
2,047_CD
1,652_CD
Deferred_JJ
tax_NN
assets_NN
Intercompany_NN
inventory_NN
transfers_NN
643_CD
527_CD
Non-UK_JJ
fixed_JJ
assets_NN
44_CD
28_CD
Accrued_VBN
expenses_NN
384_CD
238_CD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
94_CD
55_CD
Other_JJ
83_CD
111_CD
1,248_CD
959_CD
Deferred_JJ
tax_NN
liability_NOMZ
net_JJ
799_CD
693_CD
No_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
,_,
in_PIN
accordance_NN
with_PIN
FRS_NN
19_CD
,_,
for_PIN
rolled_VBN
over_IN
gains_NN
amounting_VBG [WZPRES]
to_TO
$_$
106m_CD
2003_CD
$_$
131m_CD
,_,
2002_CD
$_$
118m_CD
._.
